ReviewScience translational medicine2022
Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy.
Review in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 50 citations in OpenAlex.
- Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer.Nature cancer · 2025Trial
- Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432).Signal transduction and targeted therapy · 2024Trial
- ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.Nature medicine · 2023Trial
- Risk factors and mechanisms of immune checkpoint inhibitor-related pneumonitis.Human vaccines & immunotherapeutics · 2025Review
- A Comprehensive Oncological Biomarker Framework Guiding Precision Medicine.Biomolecules · 2025Review
- Of Context, Quality, and Complexity: Fine-Combing Tumor Mutational Burden in Immunotherapy-Treated Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Review
- Impact of metabolic and nutritional disorders on the synergy between radiotherapy and immunotherapy in non-small-cell lung cancer.BMC cancer · 2025Article
- Overview on biomarkers for immune oncology drugs.Exploration of targeted anti-tumor therapy · 2025Review
- Local Exosome Inhibition Potentiates Mild Photothermal Immunotherapy Against Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Discovery of a DNA repair-associated radiosensitivity index for predicting radiotherapy efficacy in breast cancer.Frontiers in oncology · 2025Article
- Quantitative peripheral live single T-cell dynamic polyfunctionality profiling predicts lung cancer checkpoint immunotherapy treatment response and clinical outcomes.Translational lung cancer research · 2024Article
- Review
- Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Opportunities and challenges of using circulating tumor DNA to predict lung cancer immunotherapy efficacy.Journal of cancer research and clinical oncology · 2024Review
- A Review of Immunotherapy for Head and Neck Cancer.Journal of dental research · 2024Review
- Tumour mutational burden: clinical utility, challenges and emerging improvements.Nature reviews. Clinical oncology · 2024Review
- Circulating tumor DNA (ctDNA)-the next generation biomarker in non-small cell lung cancer patients treated with immunotherapy?Translational lung cancer research · 2024Article
- ImmunoPET imaging of LAG-3 expression in tumor microenvironment withJournal for immunotherapy of cancer · 2024Article
- Review
- Thermophoretic glycan profiling of extracellular vesicles for triple-negative breast cancer management.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapeutics, triggering studies to understand the molecular and cellular wiring of response and resistance. Our increased understanding of the underlying biology of response to ICI has enabled the investigation of tumor-intrinsic and -extrinsic features that may predict therapeutic outcomes. In parallel, liquid biopsy measurements of circulating tumor DNA (ctDNA) can be used to assess real-time molecular responses and guide clinical decisions during ICI. The combination of these approaches provides a deeper understanding of cancer biology, immunoediting, and evolution during ICI and promise to extend the utility of immunotherapies for patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.